Clinical trial NCT05674474: A Study of Vorasidenib in Participants With Moderate or Mild Hepatic Impairment and Matched Participants With Normal Hepatic Function
Official title: A Phase 1, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a 20-mg Dose of Vorasidenib in Subjects With Moderate or Mild Hepatic Impairment and Matched Subjects With Normal Hepatic Function
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Hepatic Impairment
Keywords: Vorasidenib
Lead sponsor: Servier
Sponsor class: INDUSTRY
First posted: 2023-01-06
Enrollment: 16
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The primary purpose of this study is to estimate the effect of moderate or mild hepatic impairment on the pharmacokinetic (PK) profile of a single oral dose of 20 mg vorasidenib in participants with hepatic impairment relative to healthy matched control participants with normal hepatic function.


Eligibility criteria: Inclusion Criteria for All Participants:

* Have a body mass index of 18 to 40 kilograms per square meter (kg/m\^2).
* Female participants of childbearing potential must use 2 effective methods of birth control during the study and for 90 days after the last dose of vorasidenib or be surgically sterile, or postmenopausal.
* Male participants with female partners of childbearing potential must be sterile, or willing to use 2 effective methods of birth control from Screening until at least 90 days after the last dose of the study drug, or practice abstinence during the study.
* Non-smoker or uses ≤10 cigarettes per day as judged by the investigator.
* Agree to comply with all protocol requirements for the duration of the study.
* Able to provide written informed consent prior to any procedure required by the study.

Inclusion Criteria for Healthy Participants Only:

* Have normal hepatic function.

Inclusion Criteria for Participants with Hepatic Impairment Only:

* Have chronic (more than 6 months) and stable hepatic impairment (i.e., no acute episodes of illness within 30 days before Screening due to deterioration of hepatic function) as assessed by a Child-Pugh classification score of moderate (7 to 9 points) and, if Stage 2 enrolls, mild (5 to 6 points).
* The subject has grade 0 or grade 1 hepatic encephalopathy, considered stable per investigator assessment, without exacerbation within the 6 months prior to Screening.
* The subject has a QTcF of ≤480 msec.

Exclusion Criteria for All Participants:

* Have a history or clinical manifestations of a significant neurological, renal, cardiovascular, gastrointestinal, pulmonary, hematologic, immunologic, or psychiatric disease that would preclude study participation, as judged by the investigator.
* Have a history (within 5 years) or presence of malignancy, except for adequately treated basal cell and squamous cell carcinoma of the skin.
* The subject is a woman of childbearing potential who is pregnant, lactating, or planning to become pregnant within 90 days after the last dose of study drug or the subject is on oral contraceptive pills within 14 days or 5 half-lives (whichever is longer) prior to the first dose administration and during the study.
* Have received any vaccine or used any prescription (excluding hormone replacement therapy) or over-the-counter medications, including herbal or nutritional supplements, within 30 days before the first dose of the study drug.
* Have a positive test result for hepatitis B surface antigen or antibodies to hepatitis C virus.
* Have a positive test result for the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
* Have a positive test result for human immunodeficiency virus (HIV) types 1 or 2 antibodies.
* Have used strong or moderate CYP1A2 inhibitors and/or inducers within 14 days or 5 half-lives, whichever is longer, prior to the first dose administration. .
* Have used any gastric acid reducing agents (eg, proton-pump inhibitors, H2-receptor antagonists, antacids) or drugs that can prolong the QT interval for 28 days or 5 drug half-lives (whichever is longer) prior to the first dosing and throughout the study
* Have a history of severe and/or uncontrolled ventricular arrhythmias or other factors that increase the risk of QT prolongation or arrhythmic events (e.g., heart failure, hypokalemia, family history of long QT interval syndrome).
* Have a history of alcoholism or drug abuse within 3 months before Screening or excessive alcohol consumption.
* Unable or unwilling to abstain from recreational drugs, alcohol, caffeine, xanthine-containing beverages or food (e.g., coffee, tea, chocolate, and caffeinated sodas, colas), grapefruit, grapefruit juice, Seville oranges, or products containing any of these, from 48 hours prior to study drug dosing until discharge.
* Involved in strenuous activity (i.e., \>30 minutes \[min\] per day) or contact sports within 48 hours of the first dose of the study drug or during the study.
* Have a history of relevant drug and/or food allergies (i.e., allergy to drugs with the same class effect as vorasidenib or any excipients, or any significant food allergy).
* Have received study drug in another investigational study within 30 days of dosing.

Exclusion Criteria for Participants with Hepatic Impairment Only:

* Have ascites that requires paracentesis every 4 weeks or less frequently.
* Have evidence of hepatorenal syndrome or hepatic encephalopathy.
* Have a history of incipient/planned liver transplantation within 6 months of Screening or have received a liver transplant.
* Have amylase and/or lipase levels ≥3 x upper limit of normal (ULN). Presence of 8 x ULN elevations in aspartate aminotransferase (AST), alanine aminotransferase (ALT), or bilirubin and international normalized ratio (INR) of 3.5 for the hepatic impaired group.

Primary outcomes:
measure: Maximum Observed Plasma Concentration (Cmax) of Vorasidenib
timeFrame: Day 1 before dosing (0 hour) and at multiple time points up to 504 hours post-dose
measure: Time to Reach Maximum Observed Plasma Concentration (Tmax) for Vorasidenib
timeFrame: Day 1 before dosing (0 hour) and at multiple time points up to 504 hours post-dose
measure: Area Under the Plasma Concentration Versus Time Curve (AUC) From Time 0 to the Last Quantifiable Concentration (AUC0-t) for Vorasidenib
timeFrame: Day 1 before dosing (0 hour) and at multiple time points up to 504 hours post-dose
measure: AUC From Time 0 Extrapolated to Infinity (AUC0-inf) for Vorasidenib
timeFrame: Day 1 before dosing (0 hour) and at multiple time points up to 504 hours post-dose
Secondary outcomes:
measure: Apparent Terminal Elimination Half-life (t1/2) of Vorasidenib
timeFrame: Day 1 before dosing (0 hour) and at multiple time points up to 504 hours post-dose
measure: Apparent Oral Clearance (CL/F) for Vorasidenib
timeFrame: Day 1 before dosing (0 hour) and at multiple time points up to 504 hours post-dose
measure: Apparent Volume of Distribution (Vz/F) of Vorasidenib
timeFrame: Day 1 before dosing (0 hour) and at multiple time points up to 504 hours post-dose
measure: Area Under the Unbound Plasma Concentration Versus Time Curve From Time 0 to the Last Quantifiable Concentration (AUC0-t,u) for Vorasidenib
timeFrame: Day 1 before dosing (0 hour) and at multiple time points up to 504 hours post-dose
measure: Area Under the Unbound Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUCinf,u) for Vorasidenib
timeFrame: Day 1 before dosing (0 hour) and at multiple time points up to 504 hours post-dose
measure: Maximum Observed Unbound Plasma Concentration (Cmax,u) of Vorasidenib
timeFrame: Day 1 before dosing (0 hour) and at multiple time points up to 504 hours post-dose
measure: Cmax of Metabolite AGI-69460
timeFrame: Day 1 before dosing (0 hour) and at multiple time points up to 504 hours post-dose
measure: Tmax of Metabolite AGI-69460
timeFrame: Day 1 before dosing (0 hour) and at multiple time points up to 504 hours post-dose
measure: AUC0-t for Metabolite AGI-69460
timeFrame: Day 1 before dosing (0 hour) and at multiple time points up to 504 hours post-dose
measure: AUC0-inf for Metabolite AGI-69460
timeFrame: Day 1 before dosing (0 hour) and at multiple time points up to 504 hours post-dose
measure: Number of Participants With Adverse Events (AEs)
timeFrame: Up to end of study [EOS] (up to approximately 29 days)
measure: Number of Participants With Abnormalities in Laboratory Parameters
timeFrame: Up to EOS (up to approximately 29 days)
measure: Number of Participants With Abnormalities in Vital Signs
timeFrame: Up to EOS (up to approximately 29 days)
measure: Number of Participants With Abnormalities in 12-Lead Electrocardiogram (ECG) Results
timeFrame: Up to EOS (up to approximately 29 days)
measure: Number of Participants With Abnormalities in Physical Examination Findings
timeFrame: Up to EOS (up to approximately 29 days)
Other outcomes:
Locations:
city: San Antonio
country: United States
facility: American Research Corporation
state: Texas
Study officials:
References: